Amphotericin B-loaded polymeric nanoparticles: Formulation optimization by factorial design

Pharmaceutical Development and Technology

Volumn 21, Issue 2, 2016, Pages 140-146

  Carraro, Talita Cristina Moreira Moraes ^a   Khalil, Najeh Maissar ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

Author keywords

Antifungal; Encapsulation efficiency; Nanoencapsulation; Particle size; Polydispersity index

Indexed keywords

ACETIC ACID ETHYL ESTER; AMPHOTERICIN B; MACROGOL; METHANOL; NANOPARTICLE; DRUG CARRIER; LACTIC ACID; MACROGOL DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER;

ARTICLE; CHEMICAL INTERACTION; CHEMICAL PARAMETERS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; FACTORIAL DESIGN; NANOENCAPSULATION; PARTICLE SIZE; PHASE TRANSITION; POLYMERIZATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; CHEMISTRY; MEDICINAL CHEMISTRY; PROCEDURES;

AMPHOTERICIN B; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS;

EID: 84955473556     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2014.979942     Document Type: Article

References (34)

1. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012;8:147-166.
2. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 2010; 75:1-18.
3. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009;17:2950-2962.
4. He C, Hu Y, Yin L, et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010;31:3657-3666.
5. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011;354:116-123.
6. Jain JP, Kumar N. Development of amphotericin B loaded polymersomes based on (PEG)3-PLA co-polymers: factors affecting size and in vitro evaluation. Eur J Pharm Sci 2010;40:456-465.
7. Mainardes RM, Gremião MPD, Brunetti IL, et al. Zidovudineloaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 2009;98:257-267.
8. Vassiliou AA, Papadimitriou SA, Bikiaris DN, et al. Facile synthesis of polyester-PEG triblock copolymers and preparation of amphiphilic nanoparticles as drug carriers. J Control Release 2010;148: 388-395.
9. Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, Llactide) (PLA) based nanoparticles. Eur J Pharm Biopharm 2010;75: 96-106.
10. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Progress Polym Sci 2011;36: 887-913.
11. Gupta RB, Kompella UB. Nanoparticles technology for drug delivery. 1st ed. New York: CRC Press; 2006.
12. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-515.
13. Kullberg BJ, Pauw BC. Therapy of invasive fungal infections. Neth J Med 1999;55:118-127.
14. Kafetzis DA, Velissariou IM, Stabouli S, et al. Treatment of pediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005;25:26-30.
15. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci 2008;97:2405-2425.
16. Fukui H, Koike T, Nakagawa T, et al. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nanosphere (LNS-), with commercial lipid-based formulations. Int J Pharm 2003;267:101-112.
17. Huang W, Zhang Z, Han X, et al. Ion channel behavior of amphotericin B in sterol-free and cholesterol- or ergosterolcontaining supported bilayer model membranes investigated by electrochemistry and spectroscopy. Biophys J 2002;83: 3245-3255.
18. Rodrigues CD, Casa DM, Dalmolin LF, et al. Amphotericin B-loaded poly(lactide)-poly(ethylene glycol)-blend nanoparticles: characterization and in vitro efficacy and toxicity. Cur Nanosci 2013;9:594-598.
19. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences. Clin Microbiol Infect 2008;14:25-36.
20. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine 2011;7:242-247.
21. Barratt G, Bretagne S. Optimizing efficacy of Amphotericin B through nanomodification. Int J Nanomedicine 2007;2:301-313.
22. Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009;372:76-84.
23. Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161: 505-522.
24. Hermans C, Plas DV, Everaert A, et al. Full factorial design, physicochemical characterization and biological assessment of cyclosporine A loaded cationic nanoparticles. Eur J Pharm Biopharm 2012;82:27-35.
25. Derakhshandeh K, Erfan M, Dadashzadeh S. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm 2007;66:34-41.
26. Vanderhoff JW, El Asser MS, Ugelstad J. Polymer emulsification process. US Patent 4, 177, 1979.
27. Mainardes RM, Khalil NM, Casa DM, et al. Processo de obtenção de nanopartículas poliméricas contendo o fármaco anfotericina B. PI 1107205-9 A2, Dec, 2011.
28. Casa DM, Carraro TCMM, de Camargo LEA, et al. Poly(L-lactide) nanoparticles reduce amphotericin B citotoxicity and maintains its in vitro antifungal activity. J Nanosci Nanotechnol 2015;15:848-854.
29. Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencap 2005;22: 13-24.
30. Khan Z, Al-Thabaiti SA, Obaid AY, et al. Effects of solvents on the stability and morphology of CTAB-stabilized silver nanoparticles. Col Surf A 2011;390:120-125.
31. Freytag T, Dashevsky A, Tillman L, et al. Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Control Release 2000;69:197-207.
32. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 2002;238:77-92.
33. Beck-Broichsitter M, Schmehl T, Gessler T, et al. Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. J Control Release 2012; 157:469-477.
34. Khalil NM, de Mattos AC, Carraro TC, et al. Nanotechnological strategies for the treatment of neglected diseases. Curr Pharm Des 2013;19:7316-7329.